Ignite Creation Date:
2024-05-06 @ 6:04 PM
Last Modification Date:
2024-10-26 @ 2:41 PM
Study NCT ID:
NCT05536102
Status:
RECRUITING
Last Update Posted:
2023-03-09
First Post:
2022-09-07
Brief Title:
The Effectiveness and Safety of XELOX and Tislelizumab PLD for Resectable Gastric Cancer LidingStudy
Sponsor:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Organization:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Organization Data
Organization:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Class:
OTHER
Study ID:
CSPC-DMS-GC-04
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Lead Sponsor Class:
OTHER
Responsible Party:
Qi Li
Responsible Party Title:
Chief Physician
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Old Name:
None
Old Organization:
None